Fierce BioBiotech
With $50M from Flagship Pioneering, Serif strives to write new chapter for DNA medicines
Summary
With a few chemical tweaks and some dutiful protein partners, a new biotech from Flagship Pioneering thinks it has cracked the code to turn DNA into a brand-new class of therapeutics.
With a few chemical tweaks and some dutiful protein partners, a new biotech from Flagship Pioneering thinks it has cracked the code to turn DNA into a brand-new class of therapeutics.